Jiping Wang, MD, PhD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| SIRT With Tremelimumab and Durvalumab for Resectable HCC (NCT05701488) | Jiping Wang, MD, PhD | 2023-04-21 |
Track Jiping Wang, MD, PhD automatically
Every clearance here is in the API, with alerts when new ones post.